XOMA (NASDAQ:XOMA) Stock Rating Reaffirmed by HC Wainwright

XOMA (NASDAQ:XOMA - Get Free Report)'s stock had its "buy" rating restated by investment analysts at HC Wainwright in a note issued to investors on Wednesday, Benzinga reports. They currently have a $117.00 price objective on the biotechnology company's stock. HC Wainwright's price target points to a potential upside of 301.79% from the company's current price.

Separately, StockNews.com raised shares of XOMA from a "sell" rating to a "hold" rating in a report on Wednesday, August 14th.

XOMA Stock Performance

Shares of XOMA traded up $0.47 during trading hours on Wednesday, reaching $29.12. 8,682 shares of the company traded hands, compared to its average volume of 20,775. The company has a quick ratio of 8.71, a current ratio of 8.71 and a debt-to-equity ratio of 1.15. The business has a fifty day moving average price of $28.07 and a 200-day moving average price of $26.29. XOMA has a 12-month low of $14.27 and a 12-month high of $30.50. The stock has a market capitalization of $338.93 million, a P/E ratio of -7.43 and a beta of 0.92.

XOMA (NASDAQ:XOMA - Get Free Report) last posted its quarterly earnings results on Tuesday, August 13th. The biotechnology company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.02). XOMA had a negative net margin of 128.59% and a negative return on equity of 24.50%. The firm had revenue of $11.09 million for the quarter, compared to analysts' expectations of $8.37 million. Equities analysts anticipate that XOMA will post -1.42 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of XOMA. BNP Paribas Financial Markets increased its holdings in shares of XOMA by 55.6% during the 1st quarter. BNP Paribas Financial Markets now owns 3,543 shares of the biotechnology company's stock valued at $85,000 after purchasing an additional 1,266 shares in the last quarter. Price T Rowe Associates Inc. MD acquired a new stake in XOMA during the first quarter valued at $212,000. Rhumbline Advisers raised its position in shares of XOMA by 16.0% in the second quarter. Rhumbline Advisers now owns 9,695 shares of the biotechnology company's stock worth $230,000 after acquiring an additional 1,334 shares during the period. Ellsworth Advisors LLC purchased a new stake in shares of XOMA during the 3rd quarter worth about $516,000. Finally, Bank of New York Mellon Corp boosted its stake in shares of XOMA by 3.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 62,656 shares of the biotechnology company's stock worth $1,484,000 after acquiring an additional 1,968 shares in the last quarter. 95.92% of the stock is currently owned by hedge funds and other institutional investors.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.